Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season Article Swipe
Mahrukh Imran
,
Joan Puig‐Barberà
,
Justin R. Ortiz
,
Lauren Fischer
,
Dan O’Brien
,
Machaon Bonafede
,
James A. Mansi
,
Constantina Boikos
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofac167
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofac167
Background Age-related immunosenescence may impair the immune response to vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome immune senescence in older adults. This study estimated the relative vaccine effectiveness (rVE) of MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3) vs egg-derived quadrivalent inactivated influenza vaccine (IIV4e) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) in preventing influenza-related medical encounters in the 2019–2020 US season. Methods This retrospective cohort study used electronic medical records linked to pharmacy and medical claims data. The study population included adults age ≥65 years with a record of aIIV3, IIV4e, or HD-IIV3 vaccination. A doubly robust inverse probability of treatment weighting model was used to derive adjusted odds ratios (ORs). rVE was calculated by (1 – ORadjusted)*100 and was determined overall and separately for age subgroups. An exploratory analysis evaluated the outcome separately in inpatient and outpatient settings. Results Subjects received aIIV3 (n = 936 508), IIV3e (n = 651 034), and HD-IIV3 (n = 1 813 819), and influenza-related medical encounters were recorded in 0.5%, 0.9%, and 0.7% of each cohort, respectively. Overall, the rVE of aIIV3 was 27.5% (95% CI, 24.4% to 30.5%) vs IIV4e and 13.9% (95% CI, 10.7% to 17.0%) vs HD-IIV3. aIIV3 had a more favorable rVE in inpatient and outpatient settings. Findings remained consistent across age subgroups and during alternative seasonal dates. Conclusions Adults age ≥65 years vaccinated with aIIV3 had fewer influenza-related medical encounters compared with IIV4e or HD-IIV3 during the 2019–2020 US influenza season.
Related Topics
Concepts
Medicine
Influenza vaccine
Vaccination
Seasonal influenza
Medical record
Internal medicine
Population
Outpatient clinic
Cohort
Immunology
Environmental health
Coronavirus disease 2019 (COVID-19)
Infectious disease (medical specialty)
Disease
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofac167
- https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdf
- OA Status
- gold
- Cited By
- 15
- References
- 38
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4225307264
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4225307264Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofac167Digital Object Identifier
- Title
-
Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza SeasonWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-04-02Full publication date if available
- Authors
-
Mahrukh Imran, Joan Puig‐Barberà, Justin R. Ortiz, Lauren Fischer, Dan O’Brien, Machaon Bonafede, James A. Mansi, Constantina BoikosList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofac167Publisher landing page
- PDF URL
-
https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdfDirect OA link when available
- Concepts
-
Medicine, Influenza vaccine, Vaccination, Seasonal influenza, Medical record, Internal medicine, Population, Outpatient clinic, Cohort, Immunology, Environmental health, Coronavirus disease 2019 (COVID-19), Infectious disease (medical specialty), DiseaseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
15Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 4, 2024: 3, 2023: 5, 2022: 3Per-year citation counts (last 5 years)
- References (count)
-
38Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4225307264 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofac167 |
| ids.doi | https://doi.org/10.1093/ofid/ofac167 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35493131 |
| ids.openalex | https://openalex.org/W4225307264 |
| fwci | 3.36632413 |
| type | article |
| title | Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season |
| biblio.issue | 5 |
| biblio.volume | 9 |
| biblio.last_page | ofac167 |
| biblio.first_page | ofac167 |
| topics[0].id | https://openalex.org/T10167 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Influenza Virus Research Studies |
| topics[1].id | https://openalex.org/T11171 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9926000237464905 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1311 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Diabetes and associated disorders |
| topics[2].id | https://openalex.org/T11243 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9782999753952026 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Respiratory viral infections research |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9043666124343872 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2780689484 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7342092394828796 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q383260 |
| concepts[1].display_name | Influenza vaccine |
| concepts[2].id | https://openalex.org/C22070199 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7078892588615417 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q192995 |
| concepts[2].display_name | Vaccination |
| concepts[3].id | https://openalex.org/C3018751465 |
| concepts[3].level | 5 |
| concepts[3].score | 0.6636937856674194 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q4120645 |
| concepts[3].display_name | Seasonal influenza |
| concepts[4].id | https://openalex.org/C195910791 |
| concepts[4].level | 2 |
| concepts[4].score | 0.49318236112594604 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1324077 |
| concepts[4].display_name | Medical record |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4794798791408539 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2908647359 |
| concepts[6].level | 2 |
| concepts[6].score | 0.444191575050354 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[6].display_name | Population |
| concepts[7].id | https://openalex.org/C3020110884 |
| concepts[7].level | 2 |
| concepts[7].score | 0.43825381994247437 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q695416 |
| concepts[7].display_name | Outpatient clinic |
| concepts[8].id | https://openalex.org/C72563966 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4233798086643219 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[8].display_name | Cohort |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3762933909893036 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C99454951 |
| concepts[10].level | 1 |
| concepts[10].score | 0.12936589121818542 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[10].display_name | Environmental health |
| concepts[11].id | https://openalex.org/C3008058167 |
| concepts[11].level | 4 |
| concepts[11].score | 0.09238016605377197 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[11].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[12].id | https://openalex.org/C524204448 |
| concepts[12].level | 3 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[12].display_name | Infectious disease (medical specialty) |
| concepts[13].id | https://openalex.org/C2779134260 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[13].display_name | Disease |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9043666124343872 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/influenza-vaccine |
| keywords[1].score | 0.7342092394828796 |
| keywords[1].display_name | Influenza vaccine |
| keywords[2].id | https://openalex.org/keywords/vaccination |
| keywords[2].score | 0.7078892588615417 |
| keywords[2].display_name | Vaccination |
| keywords[3].id | https://openalex.org/keywords/seasonal-influenza |
| keywords[3].score | 0.6636937856674194 |
| keywords[3].display_name | Seasonal influenza |
| keywords[4].id | https://openalex.org/keywords/medical-record |
| keywords[4].score | 0.49318236112594604 |
| keywords[4].display_name | Medical record |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.4794798791408539 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/population |
| keywords[6].score | 0.444191575050354 |
| keywords[6].display_name | Population |
| keywords[7].id | https://openalex.org/keywords/outpatient-clinic |
| keywords[7].score | 0.43825381994247437 |
| keywords[7].display_name | Outpatient clinic |
| keywords[8].id | https://openalex.org/keywords/cohort |
| keywords[8].score | 0.4233798086643219 |
| keywords[8].display_name | Cohort |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.3762933909893036 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/environmental-health |
| keywords[10].score | 0.12936589121818542 |
| keywords[10].display_name | Environmental health |
| keywords[11].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[11].score | 0.09238016605377197 |
| keywords[11].display_name | Coronavirus disease 2019 (COVID-19) |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofac167 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofac167 |
| locations[1].id | pmid:35493131 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Open forum infectious diseases |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35493131 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9045943 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Open Forum Infect Dis |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9045943 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5053725425 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2478-0182 |
| authorships[0].author.display_name | Mahrukh Imran |
| authorships[0].affiliations[0].raw_affiliation_string | Seqirus Inc., Kirkland, Quebec, Canada |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mahrukh Imran |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Seqirus Inc., Kirkland, Quebec, Canada |
| authorships[1].author.id | https://openalex.org/A5033658596 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5783-0409 |
| authorships[1].author.display_name | Joan Puig‐Barberà |
| authorships[1].countries | ES |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210097149 |
| authorships[1].affiliations[0].raw_affiliation_string | Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain |
| authorships[1].institutions[0].id | https://openalex.org/I4210097149 |
| authorships[1].institutions[0].ror | https://ror.org/0116vew40 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210097149 |
| authorships[1].institutions[0].country_code | ES |
| authorships[1].institutions[0].display_name | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Joan Puig-Barbera |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain |
| authorships[2].author.id | https://openalex.org/A5001336078 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3138-5965 |
| authorships[2].author.display_name | Justin R. Ortiz |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I126744593 |
| authorships[2].affiliations[0].raw_affiliation_string | University of Maryland School of Medicine, Baltimore, Maryland, USA |
| authorships[2].institutions[0].id | https://openalex.org/I126744593 |
| authorships[2].institutions[0].ror | https://ror.org/04rq5mt64 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I126744593 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | University of Maryland, Baltimore |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Justin R Ortiz |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | University of Maryland School of Medicine, Baltimore, Maryland, USA |
| authorships[3].author.id | https://openalex.org/A5090855420 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Lauren Fischer |
| authorships[3].affiliations[0].raw_affiliation_string | Veradigm, Chicago, Illinois, USA |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lauren Fischer |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Veradigm, Chicago, Illinois, USA |
| authorships[4].author.id | https://openalex.org/A5102797033 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Dan O’Brien |
| authorships[4].affiliations[0].raw_affiliation_string | Veradigm, Chicago, Illinois, USA |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Dan O’Brien |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Veradigm, Chicago, Illinois, USA |
| authorships[5].author.id | https://openalex.org/A5078134055 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-6330-6718 |
| authorships[5].author.display_name | Machaon Bonafede |
| authorships[5].affiliations[0].raw_affiliation_string | Veradigm, Chicago, Illinois, USA |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Machaon Bonafede |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Veradigm, Chicago, Illinois, USA |
| authorships[6].author.id | https://openalex.org/A5002503150 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-7650-6778 |
| authorships[6].author.display_name | James A. Mansi |
| authorships[6].affiliations[0].raw_affiliation_string | Seqirus Inc., Kirkland, Quebec, Canada |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | James A Mansi |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Seqirus Inc., Kirkland, Quebec, Canada |
| authorships[7].author.id | https://openalex.org/A5025152489 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-8091-9193 |
| authorships[7].author.display_name | Constantina Boikos |
| authorships[7].affiliations[0].raw_affiliation_string | Seqirus Inc., Kirkland, Quebec, Canada |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Constantina Boikos |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Seqirus Inc., Kirkland, Quebec, Canada |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10167 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Influenza Virus Research Studies |
| related_works | https://openalex.org/W3118529832, https://openalex.org/W2078461378, https://openalex.org/W2019574320, https://openalex.org/W2610793451, https://openalex.org/W2029074520, https://openalex.org/W4318814642, https://openalex.org/W3132683572, https://openalex.org/W2305717397, https://openalex.org/W1990147563, https://openalex.org/W2609269943 |
| cited_by_count | 15 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 4 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 5 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1093/ofid/ofac167 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofac167 |
| primary_location.id | doi:10.1093/ofid/ofac167 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://academic.oup.com/ofid/article-pdf/9/5/ofac167/43471946/ofac167.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofac167 |
| publication_date | 2022-04-02 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W4236317939, https://openalex.org/W2774380382, https://openalex.org/W4211222382, https://openalex.org/W4211031111, https://openalex.org/W3161793057, https://openalex.org/W2587450581, https://openalex.org/W1982855609, https://openalex.org/W1973905472, https://openalex.org/W2904715936, https://openalex.org/W3007037952, https://openalex.org/W2948147686, https://openalex.org/W2981707952, https://openalex.org/W2948594359, https://openalex.org/W1983472430, https://openalex.org/W2163192885, https://openalex.org/W2125252433, https://openalex.org/W3130850400, https://openalex.org/W2606900230, https://openalex.org/W2802538780, https://openalex.org/W2168805652, https://openalex.org/W2163278718, https://openalex.org/W2951360390, https://openalex.org/W1783351295, https://openalex.org/W2061326496, https://openalex.org/W2165037395, https://openalex.org/W2110818436, https://openalex.org/W2144387798, https://openalex.org/W1608465646, https://openalex.org/W2089659047, https://openalex.org/W2770870512, https://openalex.org/W2790307992, https://openalex.org/W1979195886, https://openalex.org/W3128046729, https://openalex.org/W3098825314, https://openalex.org/W2109801797, https://openalex.org/W3006614329, https://openalex.org/W2904354111, https://openalex.org/W2785073138 |
| referenced_works_count | 38 |
| abstract_inverted_index.1 | 160 |
| abstract_inverted_index.= | 148, 153, 159 |
| abstract_inverted_index.A | 98 |
| abstract_inverted_index.a | 90, 203 |
| abstract_inverted_index.(1 | 119 |
| abstract_inverted_index.(n | 147, 152, 158 |
| abstract_inverted_index.An | 131 |
| abstract_inverted_index.US | 63, 244 |
| abstract_inverted_index.by | 118 |
| abstract_inverted_index.in | 11, 23, 55, 60, 138, 169, 207 |
| abstract_inverted_index.of | 34, 92, 103, 174, 181 |
| abstract_inverted_index.or | 95, 239 |
| abstract_inverted_index.to | 9, 19, 75, 109, 188, 197 |
| abstract_inverted_index.vs | 41, 190, 199 |
| abstract_inverted_index.651 | 154 |
| abstract_inverted_index.813 | 161 |
| abstract_inverted_index.936 | 149 |
| abstract_inverted_index.CI, | 186, 195 |
| abstract_inverted_index.The | 81 |
| abstract_inverted_index.age | 86, 129, 216, 225 |
| abstract_inverted_index.and | 48, 77, 122, 126, 140, 156, 163, 172, 192, 209, 218 |
| abstract_inverted_index.are | 17 |
| abstract_inverted_index.for | 128 |
| abstract_inverted_index.had | 202, 231 |
| abstract_inverted_index.may | 4 |
| abstract_inverted_index.rVE | 115, 180, 206 |
| abstract_inverted_index.the | 6, 29, 61, 135, 179, 242 |
| abstract_inverted_index.was | 107, 116, 123, 183 |
| abstract_inverted_index.– | 120 |
| abstract_inverted_index.(95% | 185, 194 |
| abstract_inverted_index.0.7% | 173 |
| abstract_inverted_index.This | 26, 66 |
| abstract_inverted_index.each | 175 |
| abstract_inverted_index.more | 204 |
| abstract_inverted_index.odds | 112 |
| abstract_inverted_index.used | 70, 108 |
| abstract_inverted_index.were | 167 |
| abstract_inverted_index.with | 89, 229, 237 |
| abstract_inverted_index.(rVE) | 33 |
| abstract_inverted_index.0.5%, | 170 |
| abstract_inverted_index.0.9%, | 171 |
| abstract_inverted_index.034), | 155 |
| abstract_inverted_index.10.7% | 196 |
| abstract_inverted_index.13.9% | 193 |
| abstract_inverted_index.24.4% | 187 |
| abstract_inverted_index.27.5% | 184 |
| abstract_inverted_index.508), | 150 |
| abstract_inverted_index.819), | 162 |
| abstract_inverted_index.IIV3e | 151 |
| abstract_inverted_index.IIV4e | 191, 238 |
| abstract_inverted_index.aIIV3 | 146, 182, 201, 230 |
| abstract_inverted_index.data. | 80 |
| abstract_inverted_index.fewer | 232 |
| abstract_inverted_index.model | 106 |
| abstract_inverted_index.older | 12, 24 |
| abstract_inverted_index.study | 27, 69, 82 |
| abstract_inverted_index.years | 88, 227 |
| abstract_inverted_index.≥65 | 87, 226 |
| abstract_inverted_index.(ORs). | 114 |
| abstract_inverted_index.17.0%) | 198 |
| abstract_inverted_index.30.5%) | 189 |
| abstract_inverted_index.Adults | 224 |
| abstract_inverted_index.IIV4e, | 94 |
| abstract_inverted_index.aIIV3, | 93 |
| abstract_inverted_index.across | 215 |
| abstract_inverted_index.adults | 85 |
| abstract_inverted_index.claims | 79 |
| abstract_inverted_index.cohort | 68 |
| abstract_inverted_index.dates. | 222 |
| abstract_inverted_index.derive | 110 |
| abstract_inverted_index.doubly | 99 |
| abstract_inverted_index.during | 219, 241 |
| abstract_inverted_index.immune | 7, 21 |
| abstract_inverted_index.impair | 5 |
| abstract_inverted_index.linked | 74 |
| abstract_inverted_index.ratios | 113 |
| abstract_inverted_index.record | 91 |
| abstract_inverted_index.robust | 100 |
| abstract_inverted_index.(IIV4e) | 47 |
| abstract_inverted_index.(aIIV3) | 40 |
| abstract_inverted_index.HD-IIV3 | 96, 157, 240 |
| abstract_inverted_index.Methods | 65 |
| abstract_inverted_index.Results | 143 |
| abstract_inverted_index.adults. | 13, 25 |
| abstract_inverted_index.cohort, | 176 |
| abstract_inverted_index.inverse | 101 |
| abstract_inverted_index.medical | 58, 72, 78, 165, 234 |
| abstract_inverted_index.outcome | 136 |
| abstract_inverted_index.overall | 125 |
| abstract_inverted_index.records | 73 |
| abstract_inverted_index.season. | 64, 246 |
| abstract_inverted_index.vaccine | 31, 39, 46, 53 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Findings | 212 |
| abstract_inverted_index.HD-IIV3. | 200 |
| abstract_inverted_index.Overall, | 178 |
| abstract_inverted_index.Subjects | 144 |
| abstract_inverted_index.adjusted | 111 |
| abstract_inverted_index.analysis | 133 |
| abstract_inverted_index.compared | 236 |
| abstract_inverted_index.designed | 18 |
| abstract_inverted_index.included | 84 |
| abstract_inverted_index.overcome | 20 |
| abstract_inverted_index.pharmacy | 76 |
| abstract_inverted_index.received | 145 |
| abstract_inverted_index.recorded | 168 |
| abstract_inverted_index.relative | 30 |
| abstract_inverted_index.remained | 213 |
| abstract_inverted_index.response | 8 |
| abstract_inverted_index.seasonal | 221 |
| abstract_inverted_index.vaccines | 16 |
| abstract_inverted_index.(HD-IIV3) | 54 |
| abstract_inverted_index.estimated | 28 |
| abstract_inverted_index.evaluated | 134 |
| abstract_inverted_index.favorable | 205 |
| abstract_inverted_index.high-dose | 49 |
| abstract_inverted_index.influenza | 15, 38, 45, 52, 245 |
| abstract_inverted_index.inpatient | 139, 208 |
| abstract_inverted_index.settings. | 142, 211 |
| abstract_inverted_index.subgroups | 217 |
| abstract_inverted_index.treatment | 104 |
| abstract_inverted_index.trivalent | 36, 50 |
| abstract_inverted_index.weighting | 105 |
| abstract_inverted_index.Adjuvanted | 14 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.calculated | 117 |
| abstract_inverted_index.consistent | 214 |
| abstract_inverted_index.determined | 124 |
| abstract_inverted_index.electronic | 71 |
| abstract_inverted_index.encounters | 59, 166, 235 |
| abstract_inverted_index.outpatient | 141, 210 |
| abstract_inverted_index.population | 83 |
| abstract_inverted_index.preventing | 56 |
| abstract_inverted_index.senescence | 22 |
| abstract_inverted_index.separately | 127, 137 |
| abstract_inverted_index.subgroups. | 130 |
| abstract_inverted_index.vaccinated | 228 |
| abstract_inverted_index.2019–2020 | 62, 243 |
| abstract_inverted_index.Age-related | 2 |
| abstract_inverted_index.Conclusions | 223 |
| abstract_inverted_index.alternative | 220 |
| abstract_inverted_index.egg-derived | 42 |
| abstract_inverted_index.exploratory | 132 |
| abstract_inverted_index.inactivated | 37, 44, 51 |
| abstract_inverted_index.probability | 102 |
| abstract_inverted_index.vaccination | 10 |
| abstract_inverted_index.quadrivalent | 43 |
| abstract_inverted_index.vaccination. | 97 |
| abstract_inverted_index.effectiveness | 32 |
| abstract_inverted_index.respectively. | 177 |
| abstract_inverted_index.retrospective | 67 |
| abstract_inverted_index.MF59-adjuvanted | 35 |
| abstract_inverted_index.ORadjusted)*100 | 121 |
| abstract_inverted_index.immunosenescence | 3 |
| abstract_inverted_index.influenza-related | 57, 164, 233 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5053725425 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.89279509 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |